Skip to main content
Terug
Watch Compare

Vicapsys Life Sciences, Inc.

Datakwaliteit: 83%
VICP
OTC Manufacturing Chemicals
€ 1,46
€ 0,00 (0,00%)
Marktkapitalisatie: 47,26 M
Prijs
€ 1,46
Marktkapitalisatie
47,26 M
Dagbereik
52-Weeksbereik
Volume
Openen —
50D / 200D Gem.
50D / 200D Gem.

Quick Summary

Belangrijkste Punten

Negative free cash flow of -125.741,0

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio0,03
Interest Coverage-14,65

Waardering

PE (TTM)
-35,07
Onder sectorgemiddelde (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -35,1 -1,5
P/B 1,6
ROE % -53,4
Net Margin % -41,5
Rev Growth 5Y % 1,8
D/E 0,3

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -1,35 M
ROE N/A ROA -2085,47%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -125.741,0
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,03
Interest Coverage -14,65 Asset Turnover N/A
Working Capital -2,65 M Tangible Book Value -2,65 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -35,07 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -0,27%
Market Cap 47,26 M Enterprise Value 47,17 M
Per Share
EPS (Diluted TTM) -0,03 Revenue / Share N/A
FCF / Share 0,00 OCF / Share 0,00
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 9,33%
SBC-Adj. FCF -146.438 Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2023 FY2022 FY2021 FY2020
Revenue
Net Income -1,18 M -984.790,0 -236.871,0 -765.844,0
EPS (Diluted) -0,03
Gross Profit
Operating Income -1,05 M -984.790,0 -336.871,0
EBITDA
R&D Expenses 15.267,0 13.097,0 17.698,0 102.180,0
SG&A Expenses
D&A
Interest Expense 5.156,0
Income Tax

Balance Sheet

Annual, most recent first
Metric FY2023 FY2022 FY2021 FY2020
Total Assets 39.656,0 72.021,0 594.313,0 404.118,0
Total Liabilities
Shareholders' Equity -1,93 M -950.791,0 -121.651,0 -449.106,0
Total Debt 18.712,0
Cash & Equivalents 9.422,0 14.097,0 217.295,0 1.269,0
Current Assets 39.656,0 72.021,0 222.793,0 1.269,0
Current Liabilities 1,97 M 1,02 M 715.964,0 853.224,0